Clinical trials: Renal Transplant Failure
Renal Transplant Patient
Randomized Open Label Study Evaluating the Coverage by Teleconsultation Versus Standard Follow-up of Renal Transplant Patients According to a Risk Score of Early Graft Failure (KTFS)
The main objective of this study is to optimize the coverage of renal transplant patients thanks to a personalized follow-up based on a risk score of early graft failure (KTFS, Kidney Transplant Failure Score), associated with…
- Trial name
- TELEGRAFT (NCT01615900)
- Testing
- Teleconsultation / Standard consultation
- Where
- France
- Volunteers
- 155 people
- Sponsor
- Nantes University Hospital
Arteriovenous Fistula, Arteriovenous Graft
A Randomised Trial Comparing Supraclavicular Block vs Supraclavicular and Pecs II Block in Arteriovenous Grafting
This study evaluates the addition of Pecs II block to ultrasound-guided supraclavicular brachial plexus block in patients undergoing arteriovenous graft creation surgery.
- Conditions
- Arteriovenous Fistula, Arteriovenous Graft, Kidney Failure, Chronic, Renal Failure, End-stage
- Trial name
- NCT02331030
- Testing
- Supraclavicular, Pecs II block, Ropivacaine 0.5% 20ml
- Where
- Singapore
- Volunteers
- 36 people
- Sponsor
- Changi General Hospital
Liver Cirrhosis
Faecal Microbiota Transplantation for Liver Cirrhosis
The purpose is to investigate the effect of faecal microbiota transplantation (FMT) on complications, progression, and mortality of patients with liver cirrhosis.
- Trial name
- CHiFT (NCT04932577)
- Testing
- Faecal microbiota transplantation
- Where
- Denmark
- Volunteers
- 220 people
- Sponsor
- University of Aarhus
Latent Tuberculosis, End Stage Renal Disease
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
This is a prospective, single-center, single-arm, open-label study investigating the safety, compliance and pharmacokinetics of 1-month treatment of Isoniazid, Rifapentine and Vitamin B6 in renal transplant candidates.
- Conditions
- Latent Tuberculosis, End Stage Renal Disease, Renal Transplant Candidate for Right Kidney, Renal Transplant Candidate for Left Kidney
- Trial name
- NCT05411744
- Testing
- 1 month Rifapentine, Isoniazid and Vitamin B6
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Rutgers, The State University of New Jersey
Renal Transplant Failure and Rejection
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease.
- Trial name
- MODERNIZE1 (NCT07508787)
- Testing
- Siplizumab, Rabbit anti-thymocyte globulin
- Where
- 14 sites in United States, Brazil and 1 more
- Volunteers
- 120 people
- Sponsor
- Nefro Avillion Clinical Development, LLC
End-stage Renal Disease
Reducing Disparities in Access to Kidney Transplantation (RaDIANT) Regional Study
The purpose of this study is to facilitate coordination of transplant centers in North Carolina, South Carolina, and Georgia to share kidney transplant referral data in patients with End-Stage Renal Disease (ESRD) who are…
- Trial name
- NCT02389387
- Testing
- Intensive Intervention
- Volunteers
- 440 people
- Sponsor
- Emory University
Renal Transplant Failure
VisR Ultrasound for Noninvasively Monitoring Renal Allograft Health
Ten percent of American adults, more than 20 million people, have chronic kidney disease, which in the advanced state of end stage renal disease is most desirably and cost-effectively treated by kidney transplantation.
- Trial name
- NCT03079882
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of North Carolina, Chapel Hill
End Stage Renal Disease
Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease
The goal of this clinical trial is to learn if a GalKO Porcine Thymokidney can maintain renal function, without the need for dialysis, after transplantation into adult subjects with End Stage Renal Disease.
- Trial name
- NCT07696962
- Testing
- ChoironeX GalKO Porcine Thymokidney
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Xeno Holdings (US), LLC dba ChoironeX
Medication Adherence, Compliance
Compliance/Adherence After Kidney Transplant, With or With Out Med-O-Wheel™.
Background: Adherence to the immunosuppressive drug regimen is critical to the outcome after an organ transplant. Patients need to take their prescribed medications and attend their appointments with the doctor.
- Conditions
- Medication Adherence, Compliance, Medication Nonadherence, Communication
- Trial name
- C/A (NCT01709097)
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- Karolinska University Hospital
Kidney Transplant, Renal Transplant Failure
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
The purpose of this study is to assess a new test to detect antibodies which may form following kidney transplant. These antibodies can be difficult to detect as they do not cause any symptoms but can lead to kidney damage.
- Conditions
- Kidney Transplant, Renal Transplant Failure, Kidney Transplant Rejection, Frailty
- Trial name
- HLA-AB (NCT06025240)
- Testing
- cf-DNA, Immunological Events following renal transplant in older age, Determining Predictive Models for Post-transplant HLA-specific Antibody Formation
- Where
- United Kingdom
- Volunteers
- 282 people
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
Kidney Failure, Kidney Transplant
Infusion of T-Regulatory Cells in Kidney Transplant Recipients (The ONE Study)
This research study is for patients who are going to receive a kidney transplant from a living donor. After kidney transplantation, it is necessary for transplant recipients to take "immunosuppressive drugs".
- Trial name
- NCT02091232
- Testing
- T Regulatory Cell Infusion
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Massachusetts General Hospital
Transplant; Failure, Kidney
A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
The purpose of this study is to assess Alefacept in combination with alemtuzumab induction and calcineurin inhibitor and corticosteroid withdrawal.
- Trial name
- NCT01163799
- Testing
- Alefacept (ASP0485)
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Graft Rejection, Kidney Failure
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
The primary purpose of this study is to determine whether converting from calcineurin inhibitor (CNI) therapy to sirolimus therapy will be more effective than continuing calcineurin inhibitor therapy with respect to renal…
- Trial name
- NCT00369382
- Testing
- cyclosporine or tacrolimus, sirolimus
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 121 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Transplant Recipient (Kidney), Primary Kidney Transplantation
Posttranslationally Modified Fetuin-A in Urine as a Marker for Renal Dysfunction (Patients With Chronic Kidney Disease - With or Without Kidney Transplantation).
Kidney transplantation is the preferred treatment method for patients with chronic kidney disease. Standard parameters (estimated glomerular filtration, albuminuria) of renal function detection are limited by many factors…
- Trial name
- (uPTM-FetA) (NCT06950931)
- Testing
- uPTM-FeA
- Where
- Slovakia
- Volunteers
- 86 people
- Sponsor
- University Hospital, Martin
Kidney Failure
AKIN Criteria: Acute Kidney Injury After On-Pump Coronary Artery Bypass Graft (CABG)
The purpose of this study is evaluate clinical outcomes and 30-day mortality after on-pump CABG.
- Trial name
- NCT00780845
- Volunteers
- 817 people
- Sponsor
- Hospital de Base
Kidney Transplantation
Imlifidase for Highly Sensitized Kidney Transplant Recipients With a posItive crossmAtch Against a Deceased Donor: Results of Kidney Transplantations Performed in Accordance to the French Guidelines.
Imlifidase is a recombinant cysteine protease derived from Streptococcus pyogenes and produced in Escherichia coli, which has the ability to cleave and degrade all human IgGs.
- Trial name
- ISKIA (NCT07379957)
- Where
- 20 sites in France
- Volunteers
- 450 people
- Sponsor
- University Hospital, Bordeaux
End-Stage Renal Disease
Steroid Withdrawal in Pediatric Kidney Transplant Recipients
The purpose of this study is to examine the effects of withdrawing steroids on graft rejection and kidney functions in kidney transplant recipients between the ages of 0 and 20 years (prior to their 21st birthday).
- Trial name
- NCT00023244
- Testing
- Basiliximab, Cyclosporine, Tacrolimus
- Where
- 19 sites in United States, Mexico
- Volunteers
- 274 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Renal Disease
Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation
This is a single center phase I/II open label, exploratory study assessing safety and efficacy of IdeS® (Hansa Medical, Lund, Sweden) given immediately prior to kidney transplantation.
- Trial name
- NCT02426684
- Testing
- IdeS® (Imlifidase)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Cedars-Sinai Medical Center
Chronic Kidney Failure
Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction
Calcineurin inhibitors (CNI) remain the standard treatment in renal transplantation to prevent rejection. Currently the main limitation of kidney transplantation is the occurrence of chronic graft dysfunction due to the CNI…
- Trial name
- BELASBRIDGE (NCT05562869)
- Testing
- Belatacept 250 Milligram Intravenous Powder for Solution
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital
Renal Failure Chronic, Hepatitis C
Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant
Open label single center study for the donation of HCV positive kidneys to HCV negative recipients with interventional treatment to prevent HCV transmission upon transplantation.
- Trial name
- NCT03093740
- Testing
- Zepatier, Zepatier plus Sofosbuvir
- Where
- United States
- Sponsor
- Massachusetts General Hospital